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Abstract: Regenerative tissue-engineered matrix-based heart valves (TEM-based TEHVs) may become
an alternative to currently-used bioprostheses for transcatheter valve replacement. We recently identi-
fied TEM-based TEHVs-geometry as one key-factor guiding their remodeling towards successful long-
term performance or failure. While our first-generation TEHVs, with a simple, non-physiological valve-
geometry, failed over time due to leaflet-wall fusion phenomena, our second-generation TEHVs, with
a computational modeling-inspired design, showed native-like remodeling resulting in long-term perfor-
mance. However, a thorough understanding on how TEHV-geometry impacts the underlying host cell
response, which in return determines tissue remodeling, is not yet fully understood. To assess that, we here
present a comparative samples evaluation derived from our first- and second-generation TEHVs. We per-
formed an in-depth qualitative and quantitative (immuno-)histological analysis focusing on key-players
of the inflammatory and remodeling cascades (M1/M2 macrophages, ฀-SMA+- and endothelial cells).
First-generation TEHVs were prone to chronic inflammation, showing a high presence of macrophages
and ฀-SMA+-cells, hinge-area thickening, and delayed endothelialization. Second-generation TEHVs pre-
sented with negligible amounts of macrophages and ฀-SMA+-cells, absence of hinge-area thickening, and
early endothelialization. Our results suggest that TEHV-geometry can significantly influence the host
cell response by determining the infiltration and presence of macrophages and ฀-SMA+-cells, which play
a crucial role in orchestrating TEHV remodeling.
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Geometry influences inflammatory 
host cell response and remodeling 
in tissue‑engineered heart valves 
in‑vivo
Sarah E. Motta1,2,9, Emanuela S. Fioretta1,9, Valentina Lintas2, Petra E. Dijkman1, 
Monika Hilbe3, Laura Frese1, Nikola Cesarovic4,5, Sandra Loerakker6,7, Frank P. T. Baaijens6, 
Volkmar Falk4,5,8, Simon P. Hoerstrup1,2 & Maximilian Y. Emmert1,2,4,8*
Regenerative tissue‑engineered matrix‑based heart valves (TEM‑based TEHVs) may become an 
alternative to currently‑used bioprostheses for transcatheter valve replacement. We recently 
identified TEM‑based TEHVs‑geometry as one key‑factor guiding their remodeling towards successful 
long‑term performance or failure. While our first-generation TEHVs, with a simple, non‑physiological 
valve‑geometry, failed over time due to leaflet‑wall fusion phenomena, our second-generation TEHVs, 
with a computational modeling‑inspired design, showed native‑like remodeling resulting in long‑term 
performance. However, a thorough understanding on how TEHV‑geometry impacts the underlying 
host cell response, which in return determines tissue remodeling, is not yet fully understood. To 
assess that, we here present a comparative samples evaluation derived from our first- and second-
generation TEHVs. We performed an in‑depth qualitative and quantitative (immuno‑)histological 
analysis focusing on key‑players of the inflammatory and remodeling cascades (M1/M2 macrophages, 
α‑SMA+‑ and endothelial cells). First-generation TEHVs were prone to chronic inflammation, 
showing a high presence of macrophages and α‑SMA+‑cells, hinge‑area thickening, and delayed 
endothelialization. Second-generation TEHVs presented with negligible amounts of macrophages 
and α‑SMA+‑cells, absence of hinge‑area thickening, and early endothelialization. Our results suggest 
that TEHV‑geometry can significantly influence the host cell response by determining the infiltration 
and presence of macrophages and α‑SMA+‑cells, which play a crucial role in orchestrating TEHV 
remodeling.
Current transcatheter bioprosthetic heart valve replacements are based on glutaraldehyde-fixed animal-derived 
materials and are therefore associated with long-term structural degradation and limited  durability1. Addition-
ally, such bioprostheses are associated with major limitations (i.e. risk for infection and thrombosis) as they lack 
the fundamental properties of native tissues such a native-like remodeling potential, and importantly also the 
capacity for  growth1.
Heart valve tissue engineering approaches aim at the creation of biological substitutes capable of integration, 
native-like remodeling, and  growth2,3. In this context, acellular tissue-engineered heart valves (TEHVs) for in-situ 
regeneration are particularly interesting due to their off-the-shelf availability and scalability compared to classical 
autologous tissue-engineered  substitutes2–5. Notably, acellular TEHVs based on decellularized in-vitro-grown 
tissue-engineered matrices (TEM) showed promising results as pulmonary valve replacements in a translational 
animal model using transcatheter implantation  techniques6,7.
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Initially we manufactured our TEM-based TEHVs using a simple, non-physiological valve geometry (to 
which we refer to as first-generation TEHVs in this manuscript; Fig. 1A–C) for transcatheter pulmonary valve 
replacement (TPVR) in a preclinical sheep  model6. Despite the promising valve performance in the first week 
after implantation, such first-generation TEHVs showed progressive valvular insufficiency caused by leaflet-wall 
fusion phenomena and leaflet shortening over  time6. Therefore, we recently used a computational modeling 
(in-silico) approach to achieve an analytical physiological-like design, to which we refer to as second-generation 
TEM-based TEHV (Fig. 1D–F)7. Such TEHVs comprise an optimized strain distribution profile within the 
leaflets, in order to prevent tissue compaction and endure functional remodeling, thereby enabling long-term 
 performance7. Second-generation TEHVs were manufactured using the same tissue culture processes as for our 
first-generation TEHVs, including the same cell source (ovine myofibroblasts), scaffold composite (polyglycolic 
acid coated with poly-4-hydroxy butyrate), and bioreactor  technology6,7.
Remarkably, after TPVR in sheep, second-generation TEHVs demonstrated clinical-grade and preserved long-
term performance with the absence of relevant regurgitation and only minimal leaflet shortening, as predicted 
by the computational  models7. While both generations of TEM-based valves showed profound and continuous 
remodeling potential over time, comprising host cellular infiltration, neo-matrix deposition, and endotheli-
alization, first-generation TEHVs presented with maladaptive remodeling phenomena (i.e. leaflet shortening 
and thickening) starting several weeks post-implantation. To the contrary, second-generation, computational 
modeling-inspired TEHVs, exhibited tissue remodeling towards native-like configurations.
So far, previous studies have identified two important parameters that are relevant in the remodeling process 
of TEHVs. First, the  geometry7,8, which influences the stress and strain distribution in the leaflets thereby deter-
mining long-term valve functionality. Second, the presence and distribution of α-smooth muscle actin positive 
(α-SMA+) cells within the  valves9, which if over-expressed in the leaflets, induce leaflet retraction, leading to 
dysfunction and ultimate valve  failure9. However, despite the identification of these predictors, the impact and 
role of inflammatory cells in the remodeling processes, that determines  failure6 or  success7 of the implanted TEM-
based TEHVs is not yet fully understood. Hence, the in-depth understanding of the underlying inflammatory 
Figure 1.  First- and second-generation TEM-based TEHVs. (A) Schematic of the cross-section of a first-
generation TEHV comprising the nitinol stent, the valve wall, leaflet, and the characteristic acute angle of 
the hinge region (dotted square)6. Image was created using the software Tinkercad under Creative Commons 
license Non-Commercial 3.0. (B) Macroscopic appearance of a first-generation TEHV after in-vitro culture. 
(C) In the first-generation TEHV design the leaflets are exposed to compressive strain (dark blue areas in the 
coaptation and hinge regions) in radial direction. Image was re-adapted from Sanders et al.8 under the Creative 
Commons license 4.0. (D) Schematic of the cross-section of a second-generation  TEHV7, characterized by a 
more profound hinge region (dotted square). Image was created using the software Tinkercad under Creative 
Commons license Non-Commercial 3.0. (E) Macroscopic appearance of a second-generation TEHV after in-vitro 
culture performed with an insert to impose valve  geometry8. (F) In second-generation TEHV design radial 
tissue compression was limited to the hinge region, thereby not affecting the leaflets coaptation area. Image was 
re-adapted from Sanders et al.8 under the Creative Commons license 4.0.
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processes, especially during the early stages of the remodeling process, are mandatory to determine and guide 
the outcome thereby enabling safe clinical translation of TEM-based TEHVs.
Inflammatory host cells such as monocyte-derived naïve macrophages can polarize in response to the local 
mechanical and biochemical environmental stimuli and/or implanted biomaterial, and can differentiate into a 
variety of cells that have specific biological  functions10. The extreme ends of this polarization range are referred 
to as the pro-inflammatory macrophage 1 (M1) and the anti-inflammatory macrophage 2 (M2)  type11. While M1 
macrophages are typically present during an inflammatory phase, M2 cells are primarily active during reparative 
and constructive  remodeling11.
Macrophages play a pivotal role in the initiation and perpetuation of inflammation and remodeling processes, 
thereby determining either the chronicity or the resolution of the inflammatory process—and this has been 
demonstrated also for tissue-engineered implants such as vascular  grafts12–18. In these studies, M2 macrophages 
were shown to help the recruitment of tissue remodeling cells (e.g.: smooth muscle cells, endothelial cells (ECs), 
and other immune cells) by expressing anti-inflammatory cytokines, finally leading to adaptive and functional 
 remodeling13,19–23. To the contrary, the constant presence of the M1 phenotype, which gives rise to a chronic 
inflammation and scar tissue formation, will finally result into a negative or maladaptive  remodeling11.
In this study, we assessed the role and impact of inflammatory host cells on the (mal)-adaptive remodeling 
processes observed in the hinge area of TEM-based TEHVs. To achieve this, we performed an independent, 
in-depth qualitative and quantitative (immuno-)histological analysis in tissue samples derived from the hinge 
area of our previous first-6 and second-generation7 TEHV preclinical studies (Fig. 1). We analyzed key cellular 
players of the inflammatory and remodeling cascades such as M1 and M2 macrophages, α-SMA+ cells, and 
ECs. We focused our analysis on the hinge region of the TEHVs as this area is exposed to a maximum degree of 
mechanical  strain24, which is known to be a strong regulator of valvular cell behavior and  differentiation25,that 
in turn strongly influences the (mal)adaptive remodeling phenomena in TEHVs.
Results
First-generation TEHV analyses. Qualitative evaluation of inflammatory host cell infiltration. H&E and 
MG staining showed abundant cell infiltration over time throughout the valve (Fig. 2 and Supplementary Fig. 1). 
In the explanted TEHVs from the acute animals, no cellular infiltration within the valve tissue was visible (Fig. 2 
A,E,I); the only cells detected were those trapped in the fibrin thrombus (Fig. 2I, star symbol), i.e. erythrocytes 
(Fig. 2I, triangle) and leukocytes (Fig. 2I, arrow). At 8 weeks, cells were predominantly present in the wall and 
hinge regions of the valve (Fig. 2B,F). In addition, our analysis revealed a progressive colonization of cells in the 
hinge region (at 16 and 24 weeks), which further develop towards the leaflets (Fig. 2C,G,D,H). The analysis of 
the area surrounding the scaffold remnants in the hinge region showed the presence of fibrous tissue of hetero-
geneous thickness, with eosinophilic cells containing a multilobed nucleus (Fig. 2J, white arrow), multifocal or-
dered macrophages containing blue granules in the cytoplasm (Fig. 2J,L, arrow head), multinucleated giant cells 
(Fig. 2L, cross symbol), and isolated lymphocytes (small spherical nucleus with abundant dark staining) form-
ing lymph follicles (Fig. 2J–L), all indicators of an ongoing chronic inflammatory response of the host towards 
the implanted TEHV and signs of incomplete polymer degradation at 24 weeks. Over time, α-SMA expression 
decreased in the wall region and gradually increased towards the hinge region and the leaflet (Fig. 2M–P). Abun-
dant infiltration of  CD3+ T lymphocytes was observed at the 8 weeks follow-up (Fig. 2R). After 16 (Fig. 2S) and 
24 weeks (Fig. 2T), lymphocytes distribution changed from random distribution to multifocal, with clusters 
detected around polymer leftovers or in follicles. Presence of endogenous ECs was demonstrated via SEM and 
immunohistochemistry for CD31 and VWF (Supplementary Fig. 2) and was in line with the previously reported 
results for our first-generation  TEHVs6. Interestingly, at 8 weeks inhomogeneous EC coverage was observed via 
SEM, CD31 and VWF staining (Supplementary Fig. 2A–E). In addition, we observed a large number of platelets 
 (VWF+) entrapped in the pannus (Supplementary Fig. 2B). At later time-points (16 and 24 weeks), the valves 
demonstrated a confluent, homogenous and persistent spindle-shaped EC layer covering the entire surface (Sup-
plementary Fig. 2F–O) as also confirmed by the immunohistochemistry for CD31 and VWF (Supplementary 
Fig. 2F–G and K–L). Importantly, the  CD31+ ECs in the 16 weeks explants expressed the pro-thrombotic factor 
vWF (Supplementary Fig. 2G). Cutting artefacts may have prevented the complete depiction of ECs and platelets 
presence at 24 weeks for the CD31 and vWF stainings (Supplementary Fig. 2K–L), while ECs confluency could 
be confirmed by SEM imaging (Supplementary Fig. 2M–O).
Quantitative evaluation of macrophages in TEHV hinge area. Contrarily to what is observed for the control wall 
of TEHVs, the amount of cell infiltration in the hinge region, measured by cell nuclei quantification with DAPI-
staining, did not gradually decreased over time (Fig. 3A–D). The number of stained M1 slightly decreased over 
time, whereas M2 macrophages dramatically increased beyond 8 weeks approaching the total number of M1 at 
24 weeks. However, an overall prevalence of the M1 over the M2 phenotype is observed (Fig. 3E), suggesting an 
ongoing chronic inflammatory response in the hinge area of the TEHVs.
Morphological evaluation. Morphological changes of the TEHV in terms of leaflet length and hinge thickness 
were evaluated for all available time points (Table 1). Compared to the leaflet length in the acute animals (con-
trols) (Fig. 4A, black column), leaflets showed an initial shortening of 19% at the 8-weeks time point (Fig. 4A, 
grey bar) which then further progressed over time to a total shortening of approximately 70% at 24-weeks time 
point (Fig. 4A, white bar), which led to TEHVs functional failure. The hinge thickness increased over time with 
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Figure 2.  Hinge region of first-generation TEHVs at different time-points. Representative images of the 
H&E staining performed on the cross section of the valve. (A–D) 5 × magnification pictures of the hinge 
region of the valve (scale bars 500 μm). (E–H) 20 × magnification pictures of the hinge region marked by the 
dotted rectangles in panels (A–D) (scale bars 100 μm). (I–L) 40 × magnification images of the hinge region 
marked by dotted rectangles in panels (E–H) (scale bars 50 μm). Presence of contractile cells is detected with 
immunohistochemical images at 8 (N), 16 (O), and 24 (P) weeks. α-SMA+cells are already detected in the 
hinge area at the earliest time point considered and, over time, these cells are also present in the leaflet. Acute 
control valve (M) does not present α-SMA+cells. Scale bars: 500 μm, zoom: 5 × . Presence of T-lymphocytes is 
detected with immunohistochemical images at 8 (R), 16 (S), and 24 (T) weeks. Acute control valve (Q) does not 
present T-lymphocytes. T-lymphocytes cluster around polymer remnants or in follicles (yellow arrow). Scale 
bars: 100 μm, zoom: 10 × . In panel I arrow points at leukocytes, star symbol indicates fibrin, and triangle marks 
erythrocytes. In panel (J) arrow heads point at macrophages and the white arrow indicates eosinophils. In panel 
(L), the cross symbol shows multinucleated giant cells and the arrowhead macrophages.
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Second-generation TEHV analysis. Qualitative evaluation of inflammatory host cell infiltration. H&E 
and MG staining showed few and sparse infiltrated cells in the hinge region at any time point considered (Fig. 5 
and Supplementary Fig. 3). In the acute explant, few cells were detected in the fibrin clot (Fig. 5A,D,G): erythro-
cytes (Fig. 5G, triangle) and leukocytes (Fig. 5G, arrow). After 8 weeks in-vivo, cells were predominantly present 
in the wall regions of the valve, close to the native tissues (Fig. 5B,E). At 52 weeks follow-up, instead, cells were 
homogenously distributed in the different valve regions, with some cellular aggregates in the proximity of the 
few polymeric scaffold remnants (Fig. 5C,F). Cells expressing α-SMA were only detected in the wall area of the 
valve, suggesting the presence of a functional vascular wall. Independently of the time point considered, few to 
none α-SMA+ cells were detected in the hinge and leaflet region (Fig. 5J–L). In second-generation TEHVs,  CD3+ 
T lymphocytes were overall less abundant compared to first-generation valves (Fig. 5M–O). Most of the  CD3+ T 
lymphocytes were detected 8 weeks after implantation, accumulated in the pannus at the hinge area (Fig. 5N). 
After 52 weeks, only sporadic  CD3+ cells were detected (Fig. 5O). Finally and in line with our previously report-
ed  results7, second-generation TEHVs were covered by a confluent EC layer already after 8 weeks, as shown by 
SEM imaging and immunohistochemistry (Supplementary Fig. 2). Most importantly, the confluent endothelium 
was retained up to 52 weeks.
Figure 3.  Analysis of cell phenotype for the hinge area of first-generation TEHVs. Immunofluorescence images 
at the hinge area stained for M1 (red) and M2 (green) macrophages at 8 (A), 16 (B), and 24 (C) weeks follow-up. 
(D) Total cell number quantification in the wall and hinge region of first-generation TEHVs is showing an 
abundant cell presence indicating a high ongoing inflammatory response. (E) Quantification of M1 and M2 
macrophages in the hinge region at the different time-points considered shows a prevalence of M1 over M2 
subpopulation, with the number of M1 macrophages gradually decreasing over time while M2 macrophages 
is increasing. For immunofluorescence pictures: scale bars: 100 μm, zoom 1 × . For every measurement, cell 
number is normalized per μm3.
Table 1.  Overview of the available samples for first- and second-generation TEHVs. (*) Unpublished data 
derived from an independent pilot study, in which TEHVs were cultured using the same culture conditions.
Geometry
Follow-up
Acute (= control) 8 weeks 16 weeks 24 weeks 52 weeks (= 1 year) Total
First-generation n = 2 n = 2 n = 4 n = 4 n.a 12
Second-generation n = 2* n = 3* n.a n.a n = 3 8
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Quantitative evaluation of macrophages in TEHV hinge area. Quantification of the cell nuclei stained with 
DAPI (Fig. 6A–B) revealed a low number of cells in the hinge region at both 8 weeks and 52 weeks, values 
comparable to those of the wall region of the valve (Fig. 6C). Overall, a minor presence of macrophages, with a 
prevalence of M1 over M2 subpopulation (Fig. 6D) was observed, suggesting a generally negligible inflammation 
of the hinge area.
Morphological evaluation. Comparable to what was reported for first-generation THEVs, second-generation 
TEHVs displayed an initial 23% shortening of the leaflet length at 8 weeks. However, and in contrast to the 
first-generation, the shortening did not progress over time suggesting that an equilibrium of leaflet length was 
achieved in the 52 weeks tissue samples (Fig. 7A, Supplementary Table 2), which is an important parameter to 
ensure long-term valve  performance7. In addition, the hinge region (Fig. 7B) showed a 52% increase of thickness 
at 8 weeks, which however normalized to the initial control values of the acute explants after 52 weeks (Fig. 7B, 
Supplementary Table 2).
Discussion
Inflammation is an inescapable process, which naturally follows implantation of any device. Tissue-engineered 
implants designed for in-situ approaches aim at inducing a controlled inflammatory response to ultimately enable 
orchestrated healing and remodeling  cascades26. Indeed, the impact of host cells on the ongoing inflammatory 
response and remodeling process changes over time and strongly depends on the type of implanted biomaterial, 
its geometry, and also on the overall hemodynamic conditions to which it is  subjected25,27–30.
In this study, we investigated the inflammatory host cell response in two different generations of TEM-based 
TEHV explants, which have been previously implanted as pulmonary valve replacements in a translational 
sheep  model6,7. To better understand that, we performed an independent, in-depth qualitative and quantitative 
(immuno-)histological tissue analysis focusing on the key cellular players of the inflammatory and remodeling 
processes comprising M1 and M2 macrophages, α-SMA+ cells, lymphocytes, and ECs. In agreement with previ-
ously published  studies6,7, we report the active role of inflammatory and immune cells in both the regenerative 
and the maladaptive remodeling of TEM-based TEHVs. Our results indicate that for first-generation TEHVs, 
the abundance of macrophages in the hinge area is associated with a considerable number of lymphocytes and 
α-SMA+ cells and resulting tissue fibrosis. To the contrary, the physiological-like geometry of second-generation 
TEHVs resulted in a milder inflammation with a reduced presence of macrophages, lymphocytes, and α-SMA+ 
cells. These results highlight how a milder inflammatory response (represented by a limited number of mac-
rophages, lymphocytes, and α-SMA+ cells in the tissue) resulting from a more physiological-like geometry might 
elicit an adaptive remodeling of the implanted TEM-based TEHV. On the other hand, a strong inflammatory 
response with abundance of macrophages, as observed for the simplified first-generation TEHV geometry, can 
cause a maladaptive tissue remodeling, with leaflet thickening and shortening. Our main findings have been 
summarized in Fig. 8, where we highlight the differences in valve performance, in leaflet remodeling and, impor-
tantly, in the presence of M1 and M2 macrophages, α-SMA+ cells, and ECs in first- or second-generation TEHVs 
depending on the adopted geometry.
Maladaptive remodeling of first‑generation TEHVs. α-SMA+ cells have been repeatedly reported as 
a key cell type involved in leaflet shortening and retraction of  TEHVs8,31,32, however their exact role has never 
been fully elucidated so far. In this study, we have identified two potential regulators that may play an important 
Figure 4.  Tissue geometry of first-generation TEHVs. (A) Quantification of leaflet lengths from histological 
sections of first-generation TEHVs shows gradual leaflet shortening over time. (B) Quantification of hinge 
thickness from histological sections of first-generation TEHVs demonstrates increased values over time. 
Acute control TEHVs represent the initial leaflet length and hinge thickness of acutely-implanted valves. 
Measurements are expressed as average value ± standard deviation.
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Figure 5.  Hinge region of second-generation TEHVs at different time-points. Representative images of the H&E staining performed 
on the cross section of the valve. (A–C) 5 × magnification pictures of the hinge region of the valve (scale bars 500 μm). (D–F) 
20 × magnification pictures of the hinge region marked by the dotted rectangles in panels (A–C) (scale bars 100 μm). (G–I) 
40 × magnification of the hinge region marked by dotted rectangles in panels (D–F) (scale bars 50 μm). In panel (F), SP points at a hole 
left by a suture point. In panel (G), arrow points at leukocytes and triangle indicates erythrocytes. Immunohistochemical images of the 
hinge area of second-generation TEHVs stained for α-SMA at 8 weeks (K), and 52 weeks (L) follow-up. For this novel valve geometry, 
few to none α-SMA+ cells are detected in the hinge area or in the leaflet at the time-point considered. Acute control valve (G) does not 
present α-SMA+ cells. Scale bars: 500 μm, zoom: 5 × . Presence of T-lymphocytes is detected with immunohistochemical images at 8 
(N) and 52 (O) weeks. Scale bars: 100 μm, zoom: 10 × .
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Figure 6.  Analysis of cell phenotype for the hinge area of second-generation TEHVs. Immunofluorescence 
images at the hinge area stained for M1 (green) and M2 (red) macrophages at 8 weeks (A) and 52 weeks (B) 
follow-up. (C) Total cell number quantification in the wall and hinge region of second-generation TEHVs. (D) 
Quantification of M1 and M2 macrophages in the hinge region at the different time-points considered shows a 
mild prevalence of M1 over M2 positive cells. For immunofluorescence pictures: scale bars: 100 μm, zoom 1 × . 
For every measurement, cell number is normalized per μm3.
Figure 7.  Tissue geometry of second-generation TEHVs. (A) Quantification of leaflet lengths from histological 
sections of second-generation TEHVs. (B) Quantification of hinge thickness from histological sections of second-
generation TEHVs. Acute TEHVs represent the initial leaflet length and hinge thickness of acutely-implanted 
valves. Measurements are expressed as average value ± standard deviation.
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role in the infiltration and/or differentiation of α-SMA+ cells in the hinge area of our first-generation TEHVs: 
macrophages and ECs.
In first-generation valves, the chronic inflammatory response was confirmed by a general abundance of M1 
over M2 macrophages, and an overall greater number of macrophages and lymphocytes when compared to 
second-generation TEHVs. The ongoing chronic inflammation may be explained by the presence of polymeric 
scaffold remnants until the 24 weeks follow-up, that are characterized by surrounding fibrous tissue, eosinophils, 
macrophages, multinucleated giant cells and lymphocytes (Fig. 2), thus impacting on the degree of inflammation 
of the host towards the implant.
Macrophages are known to actively impact on the degree and severity of damage and fibrosis by recruit-
ing α-SMA+ cells to the inflammation  site33, and by the transition from macrophages to  myofibroblasts34. 
Figure 8.  Summary of host cell infiltration behavior in response to the geometries of first- and second-
generation TEM-based TEHVs. (A) We hypothesize that first-generation TEHVs presented a non-physiological 
geometry, which hindered the physiological formation of blood vortexes (arrows), thereby favoring the 
deposition of erythrocytes and leukocytes in the hinge region shortly after implantation. At 8 weeks follow-up, 
first-generation TEHVs showed sustained short-term performance with high expression of M1 macrophages and 
α-SMA+ cells markers. These inflammatory cells were mostly localized in the implanted TEM material, while 
few to no cells were detected in the newly formed pannus at the hinge area. Endothelialization was incomplete 
at this stage. After 24 weeks follow-up, first-generation TEHVs exhibited moderate to severe insufficiency, with a 
chronic inflammation and extensive maladaptive remodeling of the TEM material and pannus. This maladaptive 
remodeling was associated with evident hinge region thickening, abundant M1 and M2 macrophages, and 
α-SMA+ cells expression. Image was created using the software Tinkercad under Creative Commons license Non-
Commercial 3.0 and Servier Medical Art under Creative Commons license 3.0. (B) Second-generation TEHVs 
presented a computational modeling-inspired geometry, which allowed a more physiological performance of 
the TEHVs after implantation, thereby possibly favoring vortex formation and blood wash-out from the hinge 
area. After 8 weeks, second-generation TEHVs displayed sustained performance, with few M1 macrophages 
and negligible presence of M2 and α-SMA+ cells in the hinge region. At this timepoint, endothelialization of 
the valve surfaces, and in particular, of the hinge area was complete. At 52 weeks, second-generation TEHVs 
still exhibited excellent performance, with a similar cellular composition to the 8 weeks timepoint, comprising 
M1 macrophages and negligible presence of M2 and α-SMA+ cells. This inflammatory response highlighted the 
resolution and adaptive positive remodeling by the host towards second-generation TEM-based TEHVs. Image 
was created using the software Tinkercad under Creative Commons license Non-Commercial 3.0 and Servier 
Medical Art under Creative Commons license 3.0.
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Macrophages are responsible for the release of pro-inflammatory cytokines and metalloproteinases that enhance 
the inflammatory response and influence the in-vivo wound healing by contributing to myofibroblasts prolifera-
tion and  recruitment35. Briefly, in response to a tissue injury, macrophages first express the pro-inflammatory 
M1 phenotype, releasing TNF-α, IL-1β, IL-12, and IL-23. Subsequently, M2 macrophages take over by secreting 
IL-10 and TGF-β to reduce the  inflammation36. During this process, macrophages express a complex phenotype, 
where cell polarization changes from M1 to M2 over  time37, thereby actively regulating fibrotic tissue formation 
and wound  healing38. In the presented study, we observed a steady presence of M1 macrophages, associated to 
an increase in M2 macrophages over time in first-generation TEHVs. Interestingly, M2 macrophages have been 
repeatedly reported to also influence fibrosis, by undergoing macrophage-to-myofibroblast  transition34, by pro-
moting the fibrogenic activities of  fibroblasts39, and by inducing α-SMA expression in  fibroblasts40. In addition, 
in-vitro experiments co-culturing macrophages and α-SMA+ cells demonstrated reduced apoptotic rates for both 
cell types, suggesting a beneficial interaction which promotes mutual  survival41.
The strong inflammatory response and the presence of α-SMA+ cells observed in first-generation TEHVs can 
be associated to the high strain profile exerted on the matrix as well as to the incomplete endothelialization at 
the earliest time points. Physiologically, changes in mechanical milieu can influence cell differentiation mecha-
nisms, matrix remodeling, and the endothelialization process, and are often correlated to valvular  pathologies25. 
Native valvular ECs are indeed responsible for the anti-thrombogenic properties, as well as for the retention of 
the quiescent state of valvular interstitial  cells42,43. We may therefore hypothesize that the lack of ECs has caused 
the activation of the infiltrated interstitial cells towards contractile α-SMA+ cells during the early stages of TEHV 
 remodeling42,44–46. In line with our (immuno-)histological findings, we also observed leaflet shortening, hinge 
area thickening, and wall-leaflet fusion phenomena of first-generation TEHVs. These adverse remodeling events 
were assumed to be mainly triggered by the presence of contractile αSMA+ cells and may be a consequence of 
the simplified TEHV geometry, comprising a non-physiological hinge design. This may have contributed to the 
continuous thrombus deposition and pannus formation at the hinge region, which may have finally hindered 
the development of a confluent endothelium during the first 8 weeks after implantation. Notably, at every time 
point considered in our present analysis, the hinge region of first-generation TEHVs presented with an abundant 
amount of inflammation-associated cells (i.e.: leukocytes, eosinophils, macrophages, multinucleated giant cells, 
and α-SMA+ cells) which are involved in the formation of the pannus and the associated fibrotic  tissue33 (Fig. 8A).
As previously reported, first-generation TEHVs showed good early recellularization, self-repair capacity, 
and good valve performance within the first 8 weeks in-vivo. However, mild to moderate insufficiency was first 
observed at 16 weeks, and valvular performance gradually worsened over time, with moderate-to severe insuf-
ficiency at 24 weeks, which was mainly caused by wall/leaflet fusion  phenomena6 (Fig. 8A).
Taken together, the results of the present study extend our understanding of the maladaptive remodeling 
observed in our first-generation TEHVs. As highlighted by Fig. 8A, our findings support the hypothesis that 
the extended presence of M1, combined with the increasing number of M2 macrophages over time and the 
lack of a confluent endothelium in first-generation TEHVs significantly impacted valve remodeling by inducing 
myofibroblast differentiation, causing pannus formation and subsequent increase in the hinge thickness during 
the first remodeling phases.
Second‑generation TEHVs, towards a native‑like remodeling. To date, independently of the tissue 
engineering technology  used6,47–53, several studies—among which also our first-generation TEHV—reported a 
gradual loss of TEHV performance within few months after implantation, due to maladaptive tissue remod-
eling (thickening, leaflet shortening). However, here we show that the tissue analysis of our second-generation 
TEHVs did not reveal signs of pannus formation nor thickening of the hinge area. Importantly, second-genera-
tion TEHVs presented with much less leaflet shortening when compared to their first-generation counterparts. 
Notably, it appears that both TEHVs generations undergo an early shortening within the first 8 weeks, which 
then continues in the first-generation valves leading to functional failure (negative remodeling-driven continu-
ous shortening), while the leaflet length remains completely stable and unchanged over time in the second-
generation TEHVs, thereby maintaining an excellent performance profile (functional remodeling).
In fact, the improved and more physiological geometry of second-generation TEHVs is not only beneficial 
from a mechanical point of view, but also from an inflammatory host cell response perspective (Fig. 8B). Indeed, 
the long-term performance demonstrated by our second-generation  TEHVs7 was characterized by an overall 
low inflammatory cell infiltration, negligible amount of macrophages, and, importantly, the absence of α-SMA+ 
cells in the hinge region at all the time-points considered (acute, 8 weeks, and 52 weeks). This, in relation to the 
complete endothelialization of the hinge area already at 8 weeks after implantation, resulted in an overall milder 
tissue inflammation (Fig. 8B).
Finally, this controlled inflammatory response is reflected by the observation of positive tissue remodeling 
outcomes. In this regard, we previously demonstrated that, similarly to a native valve, our computational mode-
ling-inspired valve geometry can better sustain strain on the valve leaflets, thereby ensuring a more physiologi-
cal long-term  performance7. Indeed, one of the major causes of leaflet shortening has been identified in leaflet 
compression. While first-generation TEHVs showed an overall compression of the leaflet, from the coaptation to 
the hinge region, second-generation TEHV geometry could efficiently limit leaflet compression to just the coapta-
tion  area8. Second, we did neither detect thickening nor pannus formation in the hinge area. We may therefore 
hypothesize that second-generation TEHV geometry seem to better mimic native leaflet anatomy in the hinge 
area, thereby promoting the wash-out of fibrin deposits and preventing blood stagnation (Fig. 8B). The resulting 
favorable hemodynamics may therefore have enabled long-term performance of such second-generation  TEHVs7.
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8 weeks in-vivo follow-up, a turning point in the TEHV remodeling process? As highlighted by our findings both 
generations of TEHVs presented with promising cellular infiltration and self-repair (remodeling) potential up to 
8 weeks in-vivo. However, it is important to recognize that the remodeling process of first- and second-generation 
TEHV progresses into two distinct directions beyond 8 weeks (Fig. 8A,B). So far, the relevance of TEHV geom-
etry was mainly considered on a  mechanical8 and/or  functional7 level. In the present study, we demonstrate that 
the TEHV geometry also strongly influences the outcome on a host cell response level (Fig. 8A,B).
At 8 weeks post implantation, first- and second-generation TEHVs showed comparable remodeling of the 
leaflet, with similar values of leaflet lengths (23% vs. 19% shortening for first- and second-generation, respectively) 
and hinge thicknesses. To the contrary, the differences observed in the number, phenotype, and distribution of 
infiltrating cells was substantially different underscoring the importance and impact of TEHV geometry. On 
one hand, first-generation TEHVs showed abundant cell infiltration, with approximately 20 times more cells 
per μm3 than second-generation TEHVs at the same time point. Next, abundance of inflammatory cells, such as 
eosinophilic cells, M1 macrophages, α-SMA+ cells, together with lack of a confluent endothelium in the hinge 
area were detected.
On the other hand, computational modeling-inspired second-generation TEHVs demonstrated an overall 
lower cellular infiltration with the negligible presence of M1/M2 and α-SMA+ cells already 8 weeks after implanta-
tion. Remarkably, endothelialization of the hinge region was complete already at this time point. Hence, despite 
a comparable leaflet morphology, our qualitative and quantitative cell analysis indicates a substantial difference 
between the valves already at 8 weeks that resulted in two distinct remodeling outcomes (maladaptive first-
generation TEHVs versus adaptive and functional in second-generation TEHVs) beyond 8 weeks. This finding 
highlights the importance of early host cell response in controlling long-term valvular remodeling, and provides 
important insight on time and type of cells that could be included in in-silico models to further enhance the 
outcome on tissue remodeling  prediction9.
Limitations
This study is an in-depth evaluation of TEHV explants obtained from previously performed in-vivo transcatheter 
implantations of two independent  studies6,7. Consequently, the available time points and number of samples were 
limited and unpaired between the experiments (Table 1). Hence, the possibility to perform statistical analyses to 
compare first- and second-generation THEVs was limited. Despite this, we showed that both TEHVs generations 
underwent an initial leaflet shortening at 8 weeks follow-up. However, first-generation TEHVs experienced a 
progressive leaflet shortening, leading to a 70% reduction in length at 24 weeks post-implantation. To the con-
trary, leaflet shortening for second-generation TEHV did not progress over time thereby enabling the TEHV to 
remain functional for up to 1 year. This result is in line with what was previously reported for second-generation 
 TEHVs7, even though a direct comparison between these studies is not possible because of 1) the different 
amount of samples used to evaluate the leaflet length  (117 vs 3 valve explants) and 2) the different analysis tech-
niques adopted to measure the leaflet length (caliper  measurement7 vs. histology section measurement). In this 
regard, it has been showed that a collagenous tissue processed for histology (i.e.: using formaldehyde fixation 
and paraffin wax embedding) can be subjected to a 33%  shrinkage54. Our study might therefore also highlight 
the importance of choosing the most appropriate measurement strategy to precisely report explanted TEHV 
remodeling measurements. In addition, immunohistochemistry proved to be a suboptimal technique to evaluate 
the presence of ECs due to cutting artefacts that may have caused cell detachment and lack of visible staining. 
In this regard, future studies should also better assess the integrity and functionality of the ECs layer, as well as 
evaluate the presence of activated platelets and microvesicles in the plasma. In this regard, analyses of anticoagula-
tion and anti-thrombotic properties of ECs should be carefully considered when planning future in-vivo studies.
Next, we here focused our analysis on the hinge area of the TEHVs that, due to its important load-bearing 
activity, is subjected to high  deformations24. Indeed, mechanical strain is a well-known regulator of cell behavior 
and  differentiation25, and can therefore impact the (mal)adaptive remodeling phenomena in TEHVs. However, 
future in-vivo studies should consider additional time points as well as different TEHVs regions (e.g. the leaflets), 
to assess the first stages of inflammation (3–4 weeks follow up) and the resolution of the inflammatory status 
(12–24 months).
Finally, future studies should investigate how TEHV geometry will impact on the mechanical and hemo-
dynamic valvular environment, also taking into consideration blood flow patterns through the valve, to better 
understand the mechanobiology of valvular remodeling. In this context, in-depth understanding of the molecular 
pathways underlying the complex interactions between inflammatory host cells, matrix remodeling, and scaffold 
degradation processes over time, may be crucial to better predict or even to anticipate (mal)adaptive remodeling 
phenomena.
Conclusions
This study highlights the strong interplay between TEHV geometry and its related inflammatory host cell 
response, which ultimately drives the tissue remodeling outcomes in TEHVs. First-generation TEHVs, with a 
simple valve-geometry, experienced a chronic inflammatory response characterized by abundant presence of 
M1 and M2 macrophages and α-SMA+ cells, which finally led to leaflet retraction and valve insufficiency. In 
contrast, second-generation TEHVs displayed an overall lower inflammatory response with only few M1 and M2 
macrophages and α-SMA+ cells being present. These results highlight how an analytical, computational-inspired 
TEHV geometry does not only impact the mechanical strain distribution on the leaflets which is critical for valve 
performance, but also how it orchestrates host cell response towards functional remodeling, thereby enabling 
long-term performance of a TEHV. Our findings further provide important insight into the (inflammatory) host 
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cell response and the related remodeling processes of TEM-based TEHVs which represents a key requisite for 
the safe and successful clinical translation of such technologies.
Methods
In this study, we performed a pooled, in-depth analysis of TEM-based TEHV tissue explants (n = 20) from our 
previously reported in-vivo  studies6,7, as well as from additional unpublished data. The ethics committee and 
local authorities (Veterinäramt, Gesundheitsdirektion, Kanton Zürich [197/2010], Switzerland and the Regional 
Office for Health and Social Affairs Berlin, LAGeSo, Berlin; approval.
no. G0111/11) approved the previously reported in-vivo  studies6,7, which were performed in compliance 
with the Guide for the Care and Use of Laboratory Animals, published by the National Institutes of Health 
(NIH publication No. 85–23), as well as the guidelines of the European and German societies of Laboratory 
Animal Science (FELASA, GV-SOLAS) and the ARRIVE guidelines (Animal Research; Reporting of in-vivo 
Experiments). Detailed information about the manufacturing, in-vitro characterization, and in-vivo testing of 
first-5 and second-generation7 TEHV have been previously  reported6,7. Compared to first-generation  TEHVs6, 
the use of an  insert8 to impose a computational modelling-inspired valve geometry was the only difference in 
the manufacturing protocol of second-generation  TEHVs7.
According to the follow-up schemes of our in-vivo  studies6,7, a total of fifteen TEHV tissue samples (n = 15) 
were obtained from explants at the following time points: acute (considered as control), 8 weeks, 16 weeks, 
24 weeks, and 52 weeks (1 year). The overview of available samples is reported in Table 1. In addition, the tissue 
samples for the acute (n = 2) and 8 weeks time point (n = 3) of the second-generation valve were obtained from 
an independent pilot series of animals (n = 5) which has not been published before (unpublished data), and 
were produced using the same culture conditions. Qualitative and quantitative analyses have been performed as 
described below to evaluate the inflammatory host cell response to the implanted TEHVs particularly in the hinge 
region of the leaflets, as it acknowledged to be the most subjected area to maladaptive remodeling phenomena.
Qualitative tissue analysis. Samples from explanted TEHVs (Table  1) were analyzed qualitatively to 
characterize the presence of inflammatory host cells using immunofluorescence, histology, immunohistochem-
istry, and scanning electron microscopy (SEM) techniques.
(Immuno)histochemistry and immunofluorescence stainings. In brief, TEHVs samples were fixed in formalin, 
embedded into paraffin, and cut consecutively into 5 µm slices with a sliding microtome at room temperature. 
The specimens were deparaffinized by treatment with xylene followed by a series of decreasing concentrations of 
ethanol (100–50%). Cellular infiltration and tissue appearance were evaluated by using Haematoxilin and Eosin 
(H&E) and Masson Goldner (MG) staining, and CD31, von Willebrand Factor (VWF), and α-SMA staining. The 
slides were visualized by Zeiss Mirax Midi microscope (Carl Zeiss Microimaging) and assessed with Pannoramic 
Viewer (3DHistech).
To characterize the phenotype of the infiltrated cells within the explanted TEHVs, immunofluorescence 
was performed following antigen retrieval using citrate (10 mM citric acid at pH 6.0) which was then brought 
to boiling temperature (96 °C) for 20 min. Primary antibody for CCR7 (M1 marker) and CD163 (M2 marker) 
were incubated for over-night at 4 °C. After washing with PBS, secondary antibodies were applied for 2 h (Sup-
plementary Table 1). Cell nuclei were counterstained with DAPI. The stained sections were visualized using a 
fluorescence slide scanner (ZEISS Axio Scan.Z1, Carl Zeiss AG). Image processing was performed using the 
Axio Scan.Z1 ZEN lite imaging software (Blue version, 2012; Carl Zeiss AG).
Scanning electron microscopy (SEM). SEM was used to assess and confirm the degree of endothelialization for 
the two TEHVs  geometries6,7. For further details see the Supplementary Material section.
Quantitative tissue analysis. Inflammatory host cell infiltration. Cellular infiltration was quantified au-
tomatically and manually with ImageJ  software55 in three pictures across the hinge area and in two consecutive 
sections for a total thickness of 10 µm (20 × magnification; area comprising 420,000 µm2 per picture). Pictures of 
stained sections were converted into grey-value images (16-bit). Quantification was performed by counting the 
cells positive for CCR7, CD163, or a combination of both (double stained cells) and compared to the total num-
ber of cells, detected via DAPI. The total number of cells infiltrating the wall region was used as control value for 
the complete cellular infiltration in the hinge area.
Morphological evaluation. Hinge thickness and leaflet length were measured manually for both first- and sec-
ond-generation TEHVs using the Panoramic Viewer software (3DHistech, Ltd.). For both TEHVs geometries, 
hinge thickness was measured in two different sections of 5 μm each, and in three locations per section, for a 
total of 6 measurements. Leaflet length was measured in two different sections of 5 μm each, by using the highest 
number of segments possible to increase the accuracy of the measurements. Analyzed samples comprised the 
following follow-up time-points: acute, 8 weeks, 16 weeks, 24 weeks, and 52 weeks (Table 1).
Statistics. Measurements are represented as mean value ± standard deviation unless stated otherwise. Leaflet 
length and hinge thickness measurements were averaged for each sample (Supplementary Table 2).
Data availability
Data are available upon request and completion of a Materials Transfer Agreement (MTA).
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